Health Care [ 5/12 ] | Biotechnology [ 24/74 ]
NASDAQ | Common Stock
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs.
The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 dose expansion clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 dose escalation clinical trial.
It also involves in developing two earlier stage preclinical candidates, including XMT-2068 and XMT-2175.
It has strategic research and development collaborations with Janssen Biotech, Inc., Ares TradingS. A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.11 Increased by +31.25% | -0.17 Increased by +34.33% |
| Nov 5, 24 | -0.09 Increased by +66.67% | -0.18 Increased by +51.35% |
| Aug 13, 24 | -0.20 Increased by +57.45% | -0.17 Decreased by -17.65% |
| May 9, 24 | -0.16 Increased by +69.23% | -0.18 Increased by +11.11% |
| Feb 28, 24 | -0.16 Increased by +63.64% | -0.16 |
| Nov 7, 23 | -0.27 Increased by +55.74% | -0.36 Increased by +25.00% |
| Aug 8, 23 | -0.47 Increased by +14.55% | -0.44 Decreased by -6.82% |
| May 9, 23 | -0.52 Increased by +11.86% | -0.44 Decreased by -18.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 16.36 M Increased by +52.89% | -14.12 M Increased by +27.77% | Decreased by -86.28% Increased by +52.76% |
| Sep 30, 24 | 12.60 M Increased by +63.65% | -11.50 M Increased by +72.39% | Decreased by -91.29% Increased by +83.13% |
| Jun 30, 24 | 2.29 M Decreased by -78.48% | -24.27 M Increased by +55.31% | Decreased by -1.06 K% Decreased by -107.63% |
| Mar 31, 24 | 9.24 M Increased by +18.50% | -19.31 M Increased by +66.22% | Decreased by -208.83% Increased by +71.49% |
| Dec 31, 23 | 10.70 M Decreased by -27.14% | -19.54 M Increased by +57.41% | Decreased by -182.64% Increased by +41.54% |
| Sep 30, 23 | 7.70 M Increased by +38.13% | -41.66 M Increased by +30.35% | Decreased by -541.13% Increased by +49.58% |
| Jun 30, 23 | 10.65 M Increased by +148.69% | -54.31 M Decreased by -4.00% | Decreased by -509.73% Increased by +58.18% |
| Mar 31, 23 | 7.80 M Increased by +283.20% | -57.15 M Decreased by -19.10% | Decreased by -732.45% Increased by +68.92% |
This website uses cookies. To learn more about cookies, please see our privacy policy .